NASDAQ:RUBY
Delisted
Rubius Therapeutics Inc. Stock Company Profile
$0.0570
+0 (+0%)
At Close: Mar 28, 2024
Information
399 Binney Street, Suite 300
Cambridge MA 02139
617 679 9600
www.rubiustx.com
Industry: Biotechnology
Sector: Healthcare
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
